Ponesimod for the treatment of relapsing‐remitting multiple sclerosis

Abstract

Gone are the days when neurologists considering disease modifying therapy for their patients with relapsing remitting multiple sclerosis (RRMS) could only access a handful of agents that are easy to compare. This charmingly simple situation has rapidly evolved to an increased ability to access a variety of agents that are potentially suitable for the equally complex spectrum of RRMS syndromes with different clinical and radiological features. The approval of ponesimod by NICE as a first‐ or second‐line treatment for RRMS is another welcomed addition to the current agents available.